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Abstract
We sought to develop individual-level Early Warning Indicators (EWI) of virologic failure (VF) for clinicians to use
during routine care complementing WHO population-level EWI. A case-control study was conducted at a Durban
clinic. Patients after‡ 5 months of first-line antiretroviral therapy (ART) were defined as cases if they had VF [HIV-1
viral load (VL)> 1000 copies/mL] and controls (2:1) if they hadVL£ 1000 copies/mL. Pharmacy refills and pill counts
were used as adherence measures. Participants responded to a questionnaire including validated psychosocial and
symptom scales. Data were also collected from the medical record. Multivariable logistic regression models of VF
included factors associated with VF ( p< 0.05) in univariable analyses. We enrolled 158 cases and 300 controls. In the
final multivariable model, male gender, not having an active religious faith, practicing unsafe sex, having a family
member with HIV, not being pleased with the clinic experience, symptoms of depression, fatigue, or rash, low CD4
counts, family recommending HIV care, and using a TV/radio as ART reminders (compared tomobile phones) were
associatedwithVF independent of adherencemeasures. In this setting,we identified several key individual-level EWI
associated with VF including novel psychosocial factors independent of adherence measures.
Introduction
Virologic response is usually the earliest indication ofantiretroviral therapy (ART) uptake, adherence, and
overall health for individuals living with HIV in well-
resourced settings. Virologic failure (VF) may indicate
complete nonadherence to ART or can represent suboptimal
adherence, eventually resulting in HIV drug resistance
(HIVDR), which can compromise future ART options. South
Africa has made ART available for a large number of indi-
viduals with HIV. Many urban clinical programs within
South Africa have reported low rates of VF despite a high
volume of patients.1 However, as clinics in high-prevalence
areas continue to scale-up ART delivery, a growing pro-
portion of individuals with HIV will either be asymptomatic
or harder to retain in care. These populations will inevitably
challenge even the most effective programs to maintain low
levels of VF.
The factors that contribute to VF are complex and interact
at multiple levels.2,3 TheWorld Health Organization (WHO)
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developed a set of early warning indicators (EWI) designed
to identify programs and regions where HIVDR may be of
great concern.4 These EWI include retention on first-line
ART, on-time drug pickup at the pharmacy and clinic ap-
pointment keeping, and viral load (VL) suppression 12
months after ART initiation. Several countries are using EWI
in order to focus efforts towards improving healthcare
delivery in those settings with suboptimal EWI scores.4–6
Although these ‘‘system-level’’ factors are useful at a pro-
grammatic and regional level, clinicians need ‘‘individual-
level’’ factors that could help identify and predict which
patients may be at risk of VF while on ART or prior to ini-
tiation. While many studies have explored psychosocial,
structural, or clinical factors associated with clinic retention,
ART adherence or VF, none have attempted a comprehen-
sive assessment in this setting.7–9
The Risk Factors for Virological Failure (RFVF) study was
undertaken to ascertain individual-level factors associated
with VF on ART in order to develop EWI for clinicians. For
programs that lack resources for systematic VL monitoring,
these risk factors can also identify those individuals with
potential VF for more targeted use of VL monitoring.
Methods
Clinical setting
The RFVF study was conducted at McCord Hospital (MCH)
in Durban, South Africa, which is a regional referral center that
has been treating patients with ART since 2002. MCH received
partial support from the President’s Emergency Plan for AIDS
Relief and South African government funding for ART which
began in February 2004. Patients pay a monthly fee ($15 USD)
for clinic services. Routine viral load (VL) monitoring occurs 5
months after starting ART. All patients receive initial ART ed-
ucation. Pharmacy refills and pill counts are recorded for each
patient in the clinic. If the VL was£1000 copies/mL (cpm),
patients are maintained on this regimen and followed with
annual VL monitoring thereafter. If the VL was> 1000 cpm, a
repeat VL is done 1–3 months later with concurrent adherence
counseling. If the VL remains>1000 cpm, regimen changes are
considered based upon the level of adherence and resistance
testing which is performed on all cases.
Study participants
From October 2010 through June 2012, all individuals with
HIV attending the MCH HIV clinic ‡ 18 years who were re-
ceiving ‡ 5 months of their first ART regimen (substitutions
allowed for toxicity) were offered participation in this study
if they met the criteria for a case or control.
Study design
An unmatched case-control design was chosen for this
study because the rate of VF was too low to justify a pro-
spective cohort study and the intention was to allow for in-
vestigation of all potential risk factors. Cases were defined as
patients having an initial VL> 1000 cpm after ‡ 5 months of
their first ART regimen. Controls (2:1) were defined as pa-
tients with virologic suppression (VL£ 1000 cpm) on ‡ 5
months of their first ART regimen. In general, cases were
identified as having VFwithin 1–2 weeks of a visit to the clinic
(which corresponded to a pharmacy refill). These patients
were notified and enrolled into the study if they agreed to
participate within 1–2 weeks from that date. Their enrollment
date was therefore 2–3 weeks from the most recent refill.
Controls were randomly selected patients in the clinic who
met the eligibility criteria and agreed to participate. Their date
of enrollment corresponded to a pharmacy refill date.
Data collection
All participants who provided consent and were enrolled
into the study underwent a single, semi-structured interview
in their preferred languagewith the research coordinator who
was blinded to the participant’s case-control status. This in-
terview consisted of a questionnaire, validated neurocogni-
tive assessment,10 the Kessler 10 (K-10) depression scale,11
and an unannounced pill count. The questionnaire contained
demographic, socioeconomic (including a wealth index,12,13
employment, education, and cohabitants), psychosocial (in-
cluding substance abuse,14 food insecurity,15–17 traditional
African medicine use, safe sex practices, faith, stigma,18 and
intimate partner violence19) and clinic satisfaction indices.20
There were also specific questions about ART adherence and
clinic attendance based upon a modified AIDS Clinical Trials
Group (ACTG) adherence questionnaire.21 The study physi-
cian met with each patient to review their medical history, as
well as to administer the symptom screen and Karnofsky
score.22 Clinical information,1 pharmacy refill dates/quanti-
ties, and laboratory data were abstracted from medical re-
cords and entered onto a case report form (CRF). Further
details of the data collected can be found in Table 1. Study
data were managed using REDCap electronic data capture
tools hosted at Emory University.23
Statistical analysis
Two explanatory covariates were derived from the primary
data collected. The ‘‘Access’’ covariate incorporated anti-
retroviral (ARV) refill dates and quantity dispensed. This
formula was based on the medication possession ratio
(MPR)24 accounting for all refills occurring in the 180 days
following the earliest refill date until enrollment. The ‘‘Ad-
herence’’ covariate utilized the enrollment date pill count and
incorporated the dispensed pills over the previous 180
days.25,26 The primary outcome assessed in this study was the
dichotomized participant assignment as a case or control.
Separate sensitivity analyses used a VL threshold of > 50 cpm.
All variables from the questionnaire and CRF, as well as ex-
planatory covariates, were independently analyzed for their
association with the primary outcome in univariable analyses.
Although all variables were examined, only significant
( p< 0.05) and epidemiologically important factors were fur-
ther analyzed. Individual analyses by domain were under-
taken to identify appropriate variable categories, correlations,
and interactions between variables and ascertain which var-
iables have the highest likelihood of success in multivariable
models. Several logistic regressionmultivariable models were
constructed using model selection to arrive at each final
model. Model 1 (baseline factors) attempted to identify the
factors present at the initiation of ART most associated with
the primary outcome. Model 2 included all time-updated
variables except for the Access or Adherencemeasures.Model
3 included those socioeconomic and psychosocial variables
fromModel 2 that were likely to be correlated with the Access
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measure.Model 4 included those psychosocial, symptom, and
clinical variables from Model 2 that were likely to be corre-
lated with the Adherence measure. Model 5 was considered
the full model including all time-updated variables and the
Access and Adherence measures. Receiver operator charac-
teristic (ROC) curves were constructed for each model. Sub-
group analyses were performed to assess variables associated
with VF among those individuals having only 12 months of
first-line ART. All statistical analyses were performed in SAS
(SAS Institute, Version 9.3, Cary, NC).
Ethics
The RFVF study was approved by the ethics committee at
McCord Hospital and by the institutional review board at
Emory University in Atlanta, Georgia.
Results
Cohort description
Only the significant and otherwise important characteristics
of study participants are shown in Table 2. Overall, the mean
age was 39.6 years old and 64.6% were women. Over 78% re-
ceived an income and 19.0% were unemployed. Sixty-five
percent reported having a current partner, and 41.5% reported
disclosing their status to a partner. The mean (SD) K-10 score
was 12.8 (3.4) with 55.0% scoring >12. The most commonly
reported symptoms were depression (34.5%), a rash (32.5%),
and fatigue (32.1%). Nearly half (43.9%) felt their symptoms
were related to ARVs. Only 34.7% of participants had no ob-
vious neurocognitive impairment, while 35.4% had evidence of
HIV-associated dementia. Lipodystrophy was documented in
29.5% of participants. The median (IQR) CD4 count was 300.5
cell/lL (183.5–448.0), and tuberculosis was the most frequent
opportunistic infection (54.8%). Themean (SD) duration of ART
was 30.2 months (24.3). The vast majority of participants
(88.9%) used their mobile phone to remind them to take ARVs
or visit the clinic. The median (IQR) MPR was 1.03 (0.96–1.07),
and median (IQR) pill count adherence ratio was 1.12 (1.05–
1.17). Cases and controls differed substantially across all of the
domains examined using univariable comparisons.
Baseline risk factors (Model 1)
Younger age and male gender were associated with VF in
nearly all MV models (Table 3). Additional risk factors for VF
Table 1. Quantitative Measures That Were Adapted or Modified to Accommodate
Local Cultural and Language Context and Needs of the Study
Domain Measure References
Demographic Age, gender, race/ethnicity, education level,
sensory impairment assessment
ACTG Adherence21
Socioeconomic Income, employment status, occupation,
housing, transportation to clinic, payer
source for healthcare
Assets
Food insecurity15,16
ACTG Adherence21
Wealth Index12,13
Modified HFIAS index17
Psychosocial Marital status, family and partner
information, HIV disclosure, safe sex
assessment, religious faith assessment,
traditional and alternative health practice
assessment
Substance abuse assessment
Intimate partner violence assessment,
Depression scale
Clinic satisfaction survey
Stigma assessment18
ACTG Adherence21 and CAGE14
DHS Domestic Violence Module19
Kessler 1011
Dahab et al.20
Symptoms and exam Symptom assessment
Functional status
Neurocognitive testing
ACTG Adherence21
Karnofsky Performance Status22
Digit Span Forward/Backward,
Trail-Making Test A/B10
Medical history AIDS-defining conditions1, serious non-
AIDS-defining conditions, HIV-1 RNA
viral loads, CD4 T cell counts
Not applicable
Medications ARV regimens (current and previous), ART
initiation site and referral, ART education,
Adherence sessions, self-reported
Adherence questionnaire, ART refill and
ARV reminders, concomitant medications
ACTG Adherence21
Access Pharmacy refill dates and dispensed amounts
over the preceding 180 days
MPR24
Adherence Pill counts at enrolment visit Pill Count Adherence25,26
ACTG, AIDS Clinical Trials Group; ART, Antiretroviral Therapy; ARV, Antiretroviral; DHS, Demographic and Health Survey; HFIAS,
Household Food Insecurity Assessment Scale; MPR, Medication Possession Ratio.
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Table 2. Selected Cohort Characteristics for Cases and Controls
Control Case
Domain/characteristic N = 300 N = 158 p Value
Demographic
Age at enrollment (mean) 40.9 37.1 < 0.0001
Gender (%female) 71.0 52.5 0.0001
Ethnicity (%black) 98.7 99.4 0.66
Socioeconomic
Education (mean years) 10.2 11.0 0.0093
Income (%yes) 82.0 72.2 0.017
Employment (%UE) 16.0 24.7 0.033
Housing (%rent/own) 52.7 45.6 0.17
Transportation (%personal vehicle) 9.7 19.6 0.0035
Wealth Index 1 (mean) - 0.1 0.3 0.83
Wealth Index 2 (mean) 0.1 - 0.2 0.053
Payer source for ARVs (%family/spouse) 15.7 25.3 0.017
Psychosocial
Religious faith (%yes) 91.3 82.9 0.009
Religious activity (%no religion/not active) 41.7 60.8 0.0001
TM (%ever took) 58.3 56.3 0.69
Have a current partner (%yes) 60.7 73.4 0.0073
Practiced safe sex in past 6 months (%always) 95.0 84.2 0.0002
Safe sex practice (%used condoms) 56.0 69.4 0.0064
Family member HIV status (%positive) 38.0 50.0 0.017
Have an ART supporter (%yes) 11.3 22.2 0.0036
Clinic experience (%pleased) 88.0 65.2 < 0.0001
Traditional K-10 score (mean) 12.3 13.7 < 0.0001
Traditional K-10 score (%12+ ) 48.3 67.7 < 0.0001
Tired question from K-10 (%yes) 39.7 53.2 0.0075
Symptoms and exam
Fever, chills or sweats (%no) 83.7 74.7 0.025
Fatigue (%no) 76.0 52.5 < 0.0001
Memory difficulty (%no) 84.3 72.2 0.0029
Nausea or vomiting (%no) 94.3 86.1 0.0043
Diarrhea (%no) 91.7 82.3 0.0052
Felt sad or depressed (%no) 71.3 54.4 0.0004
Felt nervous or anxious (%no) 82.0 68.4 0.0014
Rash (%no) 74.7 53.8 < 0.0001
Headache (%no) 75.7 64.6 0.016
Sexual dysfunction (%no) 83.7 69.0 0.0005
Weight loss or wasting (%no) 86.7 78.5 0.032
Hair loss (%no) 95.3 89.9 0.029
Any symptom felt related to ARVs (%yes) 39.0 52.6 0.0078
Karnofsky score (mean) 97.7 95.7 0.026
Neurocognitive assessment
None 35.3 33.5 0.89
ANI/MND 30.0 29.7
HAD 34.7 36.7
Medical history and laboratory values
Tuberculosis (%yes) 54.7 55.1 1.00
Lipodystrophy (%yes) 37.0 15.2 < 0.0001
Recent CD4 count in cells/lL (median) 359.0 206.0 < 0.0001
Recent CD4 count (% ‡ 350 cells/lL) 52.0 22.8 < 0.0001
Recent HIV RNA VL copies/mL for cases (median) — 95,221
Medications
Mean ART duration (months) 33.0 24.7 < 0.0001
Initiating ARV clinic (%Sinikithemba) 92.7 84.8 0.013
Recommended ART
Doctor or nurse 42.7 44.9 0.0068
Family 19.3 31.0
Friend 16.7 10.1
Other 21.3 13.9
(continued)
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that were likely present at ART initiation included having a
treatment supporter (OR 1.991), not having or not being active
with a religious faith (1.634), having at least one family
member living with HIV (1.613), having had a family member
recommend the individual to seek ART, use of stavudine
(d4T) in the current ART regimen, and use of fluconazole
(4.973). The ROC area under the curve (AUC) for baseline risk
factors was 0.7824 (Fig. 1A).
Overall risk factors excluding Access or Adherence
measures (Model 2)
In a full MVmodel that included all domains except Access
and Adherence, the factors that were associated with VF at the
time of study enrollment included less than always practicing
safe sex (5.500), not being pleased with their clinic experience
(2.232), K-10 score > 12 (3.136), symptoms of fatigue (2.532)
and diarrhea (2.555), the absence of lipodystrophy (2.366),
having lower recent CD4 counts (12.658), having a family
member recommend the individual to seek ART, and having
used a TV or radio as a reminder to take their ARVs (3.519)
instead of amobile phone. The ROCAUCwas 0.8867 (Fig. 1B).
Access-related risk factors (Model 3)
In a MV model that included the Access measure, the fol-
lowing remained significant after adjusting for the Access
variable: practiced unsafe sex (3.108), K-10 > 12 (3.064), and
not being pleased with their clinic experience (2.584). The
ROC AUC was 0.7952 (Fig. 1C).
Adherence-related risk factors (Model 4)
Factors known to influence Adherence that remained sig-
nificant after adjusting for the Adherence variable included
Table 2. (Continued)
Control Case
Domain/characteristic N = 300 N = 158 p Value
Current ART regimen contains
Stavudine (d4T) 17.3 27.8 0.0077
Zidovudine (ZDV) 24.7 15.2
Other (tenofovir, didanosine, abacavir) 58.0 57.0
HIV education and training sessions (%3 + ) 97.3 91.1 0.0050
Adherence counseling sessions
0 or 1 session 6.0 17.8 < 0.0001
2, 3, or 4 sessions 78.0 57.3
5+ sessions 16.0 24.8
Mechanism to remember to take ARVs
Mobile phone (%yes) 91.0 84.8 0.060
TV or radio (%yes) 5.3 13.9 0.0022
Clock or watch alarm (%yes) 10.3 12.7 0.44
Other (%yes) 4.7 9.5 0.067
Fluconazole use in the past 6 months (%yes) 1.0 8.9 < 0.0001
TS use in the past 6 months (%yes) 44.7 63.9 0.0001
INH or RIF use in the past 6 months (%yes) 9.3 21.5 0.0005
ETB use in the past 6 months (%yes) 1.3 5.7 0.014
Access MPR
Median 1.03 1.00 0.83
‡Overall median (%) 49.3 42.6 0.17
‡ 90% (%) 89.3 83.5 0.10
‡ 80% (%) 96.7 94.3 0.23
‡ 70% (%) 99.0 94.9 0.010
Highest overall quartile (%) 11.0 20.7 0.2665
Upper middle overall quartile (%) 38.3 21.9
Lower middle overall quartile (%) 25.3 34.2
Lowest overall quartile (%) 25.3 23.2
Adherence pill count ratio
Median 1.13 1.08 < 0.0001
‡Overall median (%) 56.3 41.1 0.0033
‡ 90% (%) 92.7 85.4 0.020
‡ 80% (%) 94.7 88.0 0.015
‡ 70% (%) 96.0 88.6 0.0045
Highest quartile (%) 29.9 11.4 0.0008
Upper middle quartile (%) 26.4 29.8
Lower middle quartile (%) 24.0 23.4
Lowest quartile (%) 19.8 35.5
ANI, asymptomatic neurocognitive impairment; ART, ARV treatment; ARVs, antiretrovirals; ETB, ethambutol; HAD, HIV-associated
dementia; INH, isoniazid; K-10, Kessler 10 depression scale; MND, mild neurocognitive disorder; MPR, medication possession ratio; RIF,
rifampicin; TM, any form of traditional (African, Chinese, Indian) or alternative/complimentary medicine; TS, trimethoprim-
sulfamethoxazole; UE, unemployed (seeking work or not seeking work); VL, viral load.
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not having or not being active with a religious faith (1.854),
not being pleased with their clinic experience (1.934), prac-
ticed unsafe sex (5.905), K-10 > 12 (2.689), symptoms of fa-
tigue (2.471) or rash (2.011), low recent CD4 count (12.821),
family member recommended the patient to seek ART, the
use of d4T in the current regimen, and using a TV/radio as a
reminder for ARVs (3.363). The Adherence measure was also
significant (1.328). The ROC AUC was 0.8851 (Fig. 1D).
Overall risk factors including Access and Adherence
measures (Model 5)
After adjusting for both the Access and Adherence vari-
ables, the following remained associated with VF: practiced
unsafe sex (5.023), having at least one family member living
withHIV (2.000), not being pleasedwith their clinic experience
(1.965), K-10 > 12 (3.021), symptoms of fatigue (2.470) or rash
(1.992), low recent CD4 count (12.821), family member re-
commended the patient to seekART, andused a TV/radio as a
reminder for ARVs (3.681). Again, Adherence was significant
(1.311), while Access had to be removed due to high collin-
earity with Adherence. The ROC AUC was 0.8881 (Fig. 1E).
Sensitivity and subgroup analyses
The following sensitivity and subgroup analyses (data not
shown) are described in terms of how they differed from the
whole cohort analyses. When the outcome was changed to a
Table 3. Multivariable Analyses of Risk Factors for Virologic Failure Using Logistic Regression
Domain/Risk Factor Model 1 Model 2 Model 3e Model 4 Model 5
Demographic
Age (per 5 year increase) 0.956c 0.837a 0.865a 0.807b 0.860
Gender (male) 1.995c 2.262c 2.524d 2.682c 2.416c
Socioeconomic —
Education (per 1 year) 1.112 1.111 1.108
Transportation (personal) 1.771a 1.789 1.979a 2.034
Pay for care (family/spouse) 1.517 1.631
Psychosocial
Faith activity (none) 1.634b 1.722a 1.533a 1.854b 1.802b
Practice safe sex ( < always) — 5.500d 3.108c 5.905d 5.023c
Family HIV + (none) 0.620b 0.593a 0.665a 0.588a 0.500b
Treatment supporter (yes) 1.991b 1.910 1.807a 1.699 1.783
Clinic feel pleased (yes) — 0.448b 0.387d 0.517b 0.509b
Depression (12 + ) — 3.136d 3.064d 2.689c 3.021c
Symptoms and exam — —
Fatigue 2.532c 2.471c 2.470c
Diarrhea 2.555b 2.026 2.079
Sadness 1.401 1.409
Skin lesions 1.720a 2.011b 1.992b
Medical history —
Lipodystrophy (yes) — 0.428b 0.611 0.608
Log CD4 (per 1.0 increase) — 0.079d 0.078d 0.078d
Medications —
ARV duration (per 1 month) 0.995 1.001 1.007 1.008
Recommend HIV clinic
Friend vs family 0.424b 0.311b 0.279b 0.266b
Other vs family 0.446b 0.376b 0.350b 0.397b
Provider vs family 0.879b 0.760b 0.806b 0.855b
First clinic (Sinikithemba) 0.503a 0.440a 0.487
ARV training sessions (3 + ) 0.350a
Adherence counseling —
2–4 vs 0–1 0.370 0.383 0.378
5 + vs 0–1 0.416 0.470 0.419
Current regimen
ZDV vs d4T 0.619b 0.649a 0.699 0.691a
Other vs d4T 0.489b 0.455a 0.484 0.435a
Recall ARVs (TV/radio) — 3.519c 3.363b 3.681c
Trimethoprim/sulfa (yes) 1.625a 0.624
Fluconazole (yes) 4.973b 2.636 3.006
Ethambutol (yes) 2.729 2.800 3.606 3.025
Access (0.1) — — 0.962 —
Adherence (0.1) — — — 0.753b 0.763b
Odds ratios presented; ap < 0.10, bp< 0.05, cp< 0.01, dp< 0.001; eAdjusted for ARV duration which was significant; ARV, antiretroviral;
Model 1, baseline variables (excluding any time updated variables); Model 2, full model without access or adherence variables; Model 3,
socioeconomic and psychosocial adjusted for access (forced); Model 4, psychosocial, symptoms, clinical events and meds adjusted for
adherence; Model 5, full model with Access and Adherence forced; — variable or domain was excluded a priori.
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VL threshold of > 50 cpm, there were 265 controls and 193
cases (35 participants, 7.64%, were reclassified). Only six
participants had a VL between 200 and 1000 cpm. For model
1, ART duration and ethambutol (ETB) use were signifi-
cantly associatedwith VF.Models 2 and 3 did not differ from
the whole cohort models respectively. In model 4, diarrhea,
the current ART regimen, and fluconazole use were signifi-
cantly associated with VF, whereas Adherence was not sig-
nificant. In model 5, age, diarrhea, and fluconazole use were
significant, whereas Adherence was not. When only partic-
ipants with 12 months of ART were included in the analyses,
model 1 was largely unchanged. For model 2, being re-
commended by a family member to receive HIV treatment,
the absence of lipodystrophy, and symptoms of fatigue and
diarrhea were no longer significantly associated with VF. In
model 3, being employed was associated with VF. In model
4, the first clinic ART the participant received ART and the
current regimen were associated with VF whereas fatigue
and family recommendation for ART were not. Finally in
model 5, fatigue and family recommendation for ART were
not associated with VF.
Discussion
The RFVF study sought to define the individual-level de-
terminants for VF which could be used in this setting to
FIG. 1. Receiver operator characteristic curves for multivariable models 1–5 (A–E).
Table 4. Key Risk Factors
Baseline (while initiating
or suppressed on ART)
On ART without Access/
Adherence measuresa
On ART with Access/
Adherence measuresa
Age Depression Depression
Gender Unsafe sex practices Unsafe sex practices
Faith Clinic experience Clinic experience
Family member HIV + Fatigue Fatigue
Treatment supporter Diarrhea Rash
Clinic recommendation Lipodystrophy Current CD4 count
Current regimen Current CD4 count ARV reminders
Fluconazole use ARV reminders Adherence
aThese factors do not include those that were identified as baseline risk factors.
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identify patients at risk and what their specific barriers are
prior to ART initiation and while on treatment (Table 4). This
would enable targeted approaches for interventions and
could serve as surrogatemeasures for VF in settings where VL
monitoring is not available. Most of the determinants found
were consistent across a large number of models and sub-
group analyses. Key demographic, socioeconomic, psycho-
social, and clinical elements were associated with VF
independent of adherence measures.
Within the Demographic domain, younger age was a
predictor of VF at baseline and had a trend towards being
associatedwith VFwhen examining all variables but was not
independent of Access or Adherence. This indicated that age
impacts VF largely through obtaining and taking ARVs.
Poor adherence and higher rates of VF for younger indi-
viduals have been described in many different settings.27–33
Additionally, male gender was associated with VF at base-
line and in all other models confirming findings from
FIG. 2. Correlation between
Access and Adherence variables
for cases and controls. (Color for
this image can be found at www
.liebertpub.com/apc.)
FIG. 3. Schema of social, behavioral and clinical factors
related to virologic response for individuals receiving anti-
retroviral therapy (ART). Pill adherence is necessary for viral
load (VL) suppression; however, access to ART is neither
necessary nor sufficient. Individuals can obtain ART from
family or friends and may not swallow pills despite obtain-
ing them. Socioeconomic factors (i.e., transportation to clinic)
and co-morbid illnesses have a more direct effect on ART
access. Likewise, concomitant medications and psychosocial
factors (i.e., stigma, disclosure, and depression) are more
directly associated with ART adherence but also impact ART
access. Institutional (healthcare, religious, governmental),
community (neighborhood, dyadic) and societal (cultural,
infrastructure, policy) factors have more global impact at all
lower levels in this paradigm. (Color for this image can be
found at www.liebertpub.com/apc.)
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previous studies. Not always dependent on adherence, these
studies have shown men have poor health-seeking behav-
iors, higher baseline VL, lower ARV concentrations, late
presentation with advanced disease, and inadequate reten-
tion in care, although women tend to have more ARV-
related adverse events.34–39 From the Socioeconomic domain,
relying on one’s own vehicle for transportation to clinic had a
trend towards an association with VF and appeared to be
independent of the Access variable, which was unexpected
based on previous reports.9,40 It is likely that this variable is
highly correlated with another significant factor such as male
gender.
From the Psychosocial domain there were several novel
variables identified. Symptoms consistent with depression
and fatigue, as well as practicing unsafe sex, were markedly
associated with VF in all models where those variables were
examined independent of Access and Adherence. Depression
has been linked to poor adherence but is also associated with
other factors that could be independently associated with VF
such as alcohol abuse, whichwas infrequent in this study.41–43
Unsafe sex may be a marker for behaviors leading to VF such
as neglecting other health-related advice given during ART
training and adherence counseling. It could also be more di-
rectly linked with VF through HIV superinfection or sexually
transmitted infections that could cause an increase in VL.44
Not being active with a religious faith and having at least one
family member with HIV were associated with VF in all
models but was not highly significant. Religious faith has
been shown to improve adherence, but some studies have
shown that certain practices could encourage prayer in lieu of
ART.45–47 In contrast to other studies, stigma and traditional
African medicine use was not specifically identified as a risk
factor for VF.9,48,49 Although having a family member with
HIV could promote mutual support, if the family member is
ill, time, attention and ARVs may be diverted away from the
participant and to that family member.50 Individuals who
were pleased with their clinic experience were more likely to
be controls in all models as has been shown in other studies
that described the influence of the healthcare environment on
clinic attendance and adherence.9,40,51–55.
Several clinical factors were associated with VF. Low CD4
count at start of ART was highly associated with VF in all
models and independent of Access or Adherence, confirming
findings from previous studies.56 It is important to note that,
although a lowCD4 count is highly associatedwith VF, it may
be a consequence rather than a cause of VF. The absence of
lipodystrophywas found to be a risk factor for VF but was not
significant after controlling for adherence. This likely repre-
sents a strong correlation between ART adherence and fat
redistribution syndrome, contrary to a previous report from
Rwanda.57 The use of d4T was also associated with VF at
baseline when compared to TDF (most commonly used),
ZDV, ABC, and ddI. The ART regimen only had a trend to-
wards significance when more variables were included in the
model. Side effects and toxicity-related treatment discon-
tinuation may be more frequent for d4T compared to ZDV-
containing ART.58,59 Despite this finding, rates of overall
virologic suppression were not statistically inferior when
comparing d4T+ 3TC and ZDV+ddI with non-nucleoside re-
verse transcriptase inhibitor (NNRTI)59 or indinavir-containing
ART60 in previous studies. TDF-containing regimens have been
shown to be better tolerated and have fewer side effects than
d4T-containing ART but comparably effective.61,62 However,
amongst participants failing a TDF-containing regimen, we
and others reported a high rate of the K65R mutation (> 65%63
and 46%,64 respectively). This finding is under surveillance to
assess if this is a unique association in subtype C.
If a family member recommended the individual for ART,
they were more likely to be a case in all models and inde-
pendent of Access or Adherence. It is not entirely clear how
family member referral could impact treatment outcomes. It
is possible that family-driven stigma could be playing a role,
but it is more likely that this represents a lack of connection
to primary care services or access to ART such as is common
for men in this setting.65 This may alternatively reflect the
fact that this is a proxy for more symptomatic disease at
baseline prompting immediate family referral and subse-
quent association with poor outcomes. Finally, use of a tele-
vision or radio to remind individuals to take their ARVs was
suboptimal compared to using a mobile phone. Mobile phone
reminders have been shown in clinical trials to promote ad-
herence whenweekly text messaging, daily calls, or alarms are
used.66–68
Access and Adherence measures were highly correlated,
q= 0.68 ( p< 0.0001) (Fig. 2). Although poor Access (measured
by the MPR) was significant in a UV comparison (‡ 70%), it
was not significant in any of the MV models as a continuous
measure. The MPR does identify major interruptions in ART,
which is ideal for NNRTI-based therapy and was effective in
this setting for identifying second-line VF,69 but with the
limitation in mind that it does not necessarily represent the
proportion of days covered, which is amore accuratemeasure
of adherence. Suboptimal Adherence (measured by pill
count), however, was significantly associated with VF in all
models where it was examined.
When a VL > 50 cpm was used to define cases, only 35
participants were reclassified, indicating that the lower
threshold identified only a small percentage of additional cases.
A recent modeling study showed greater cost-effectiveness
when using the higher VL threshold in this setting.70 Using the
lower cutoff, diarrhea and fluconazole use were associated
with VF. While diarrhea could lead to diminished absorption,
fluconazole increases ARV concentrations. Although this
could lead to increased side effects and reduced ARV adher-
ence, this association seems less plausible. When restricting
the analyses to individuals with only 12 months of ART,
fatigue and family members recommending ART were no
longer associated with VF.
Ultimately these factors interact in highly complex ways in
determining an individual’s virologic response to ART (Fig.
3). Pill adherence is a necessary final step required for VL
suppression (assuming optimal pharmacokinetics) and can be
a reasonable surrogate for actual pills ingested, although pill
dumping has been described in this setting,71 as well as poor
counting performance by clinical staff. Access to clinic refills
as measured by the MPR is not always a reliable indicator of
adherence, as it is not necessarily indicating ingested pills and
individuals can obtain ARVs through other unmeasured
sources. Although socioeconomic barriers have been well-
described as leading to treatment interruptions, missed visits,
and poor adherence,8,72,73 these factors appear to be over-
shadowed by psychosocial and clinical factors in our study,
reinforcing the importance of a comprehensive approach to
assessing determinants of health. Socioeconomic and
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institutional barriers can often be more readily addressed
with discrete interventions (transportation and food assis-
tance or improving the clinic environment),9 whereas psy-
chosocial barriers can be more challenging to address.
There were limitations to the current study. The RFVF
study used a case-control design and as such, recall bias is a
possibility since many of the variables obtained from the
questionnaire relied upon a participant’s recollection of
events that had occurred over the past 6 months. Moreover,
causality has not been established through this analysis, and
in fact, reverse causation may even exist. Despite this sug-
gestion, we have identified surrogate markers that can be
used by large programs to focus their counseling and moni-
toring efforts on those individuals at risk before VF or HIVDR
occurs. Althoughmost cases were told of their virologic status
within a week or two prior to their interview, this could have
impacted some of the responses about overall well-being.
While we did not assess for HIVDR prior to ART initiation,
which could be a risk factor for VF within the first 6 months of
ART initiation, the rates of transmitted HIVDR have been
reportedly low to non-existent in KwaZulu-Natal.74 Further-
more, baseline HIV genotyping is not routinely available in
South Africa and could therefore not be integrated into clin-
ical algorithms at this time. Finally, only one clinical site was
examined, which does not permit comparisons across diverse
programs or geographic settings (rural or peri-urban).
In summary, the RFVF study provided real-world indicators
which could be used to identify patients—either at the time of
starting ART and or while receiving ART—for VF, an event
with important long-term consequences. This would enable
programs to tailor specific interventions for individualswith the
intention to reduce the likelihood of VF and HIVDR. Further-
more, these determinants could be used in settings that do not
have resources for routine VL monitoring to assist clinicians in
making decisions about more targeted use of VL testing. It is
important to validate this questionnaire in other urban as well
as rural settings. Eventually a more refined questionnaire could
be tested prospectively in order to develop a risk score.
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